Eli Lilly and Co
XHAM:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
XHAM:LLY
Watchlist
Price: 849.1 EUR -4.4%
Market Cap: €812.2B

Net Margin

31%
Current
Improving
by 9.7%
vs 3-y average of 21.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
31%
=
Net Income
$18.4B
/
Revenue
$59.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
31%
=
Net Income
€18.4B
/
Revenue
$59.4B

Peer Comparison

Country Company Market Cap Net
Margin
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...

Market Distribution

Higher than 93% of companies in the United States of America
Percentile
93nd
Based on 15 072 companies
93nd percentile
31%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Eli Lilly and Co
Glance View

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
31%
=
Net Income
$18.4B
/
Revenue
$59.4B
What is Eli Lilly and Co's current Net Margin?

The current Net Margin for Eli Lilly and Co is 31%, which is above its 3-year median of 21.2%.

How has Net Margin changed over time?

Over the last 3 years, Eli Lilly and Co’s Net Margin has increased from 20.6% to 31%. During this period, it reached a low of 15.4% on Dec 31, 2023 and a high of 31% on Sep 30, 2025.

Back to Top